Gilead Foundation

What Gilead Foundation does

Gilead Foundation is the philanthropic arm of Gilead Sciences (NASDAQ: GILD), a biopharmaceutical company founded in 1987 and headquartered in Foster City, California. The Foundation invests in health equity, HIV prevention, STEM education, and community resilience, deploying more than $260 million across Gilead Foundation and corporate giving programs in 2025. Its work is grounded in three flagship initiatives: the Community Health Worker Comprehensive HIV Prevention Initiative (a two-year, $12 million program funding 33 community-based organizations across 14 U.S. states and D.C.), the National AIDS Memorial partnership for HIV/AIDS education and the Pedro Zamora Young Leaders Scholarship, and the STEM Careers Partnership with Boys & Girls Clubs of America.

The Foundation's programs are tightly integrated with Gilead Sciences' commercial pharmaceutical operations. Lenacapavir (branded as Yeztugo), the first twice-yearly HIV pre-exposure prophylaxis (PrEP) option approved in the U.S., underpins much of the Foundation's HIV work. Gilead supplies lenacapavir at no profit to the company through Global Fund and PEPFAR channels, while voluntary licensing agreements with six generic manufacturers (Dr. Reddy's, Emcure, Eva Pharma, Ferozsons, Hetero, Mylan/Viatris) enable supply across 120 primarily low- and lower-middle-income countries, targeting approximately $40 per person per year from 2027.

Beyond HIV, the Foundation supports the elimination of visceral leishmaniasis through a renewed WHO partnership committing $9.2M and 400,000+ vials of AmBisome through 2030, and funds programs addressing social determinants of health and healthcare workforce pathways. Distribution leverages Gilead Sciences' established channels — Global Fund, PEPFAR, regional business partners, and the Medicines Patent Pool (which Gilead joined in 2011 as its first pharmaceutical member) — enabling rapid scaling from regulatory approval to in-country delivery that is unusual for the global health sector.

Name

Gilead Foundation

Legal name

Gilead Sciences, Inc.

Website

https://gilead.com

Company type

Public

Founded year

1987

Operating status

Operating

Short description

Gilead Foundation is the philanthropic arm of Gilead Sciences, deploying more than $260 million annually in HIV prevention, health equity, STEM education, and community resilience programs across the U.S. and 120 low- and lower-middle-income countries.

Ownership category

akta.pro rank

Product category

Corporate Philanthropic Foundation

NAICS

Voluntary Health Organizations (813212), Grantmaking Foundations (813211)

SIC

Services-Social Services (8300)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Community Foundations (BPAGAKAB), Education Grantmaking Foundations (BPAGAKAK)

Keywords

• Philanthropic health grants
• HIV prevention funding
• Community health programs
• Health equity initiatives
• Corporate foundation giving

Headquarters

HQ city

Foster City

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Others, Operations, Personnel, Marketing or Sales

Revenue model

1. Pharmaceutical Medicines: Gilead Sciences, the parent company of Gilead Foundation, generates revenue through the sale of prescription medicines for HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company operates in more than 35 countries worldwide.
2. Global Health Access - No-Profit Supply: Gilead supplies lenacapavir at no profit to the company through Global Fund and PEPFAR for early access in resource-limited countries until generics are available.
3. Philanthropic Giving: Gilead Foundation and corporate giving programs invested $260M+ in 2025 supporting efforts addressing social determinants of health, STEM education, healthcare workforce pathways, food security, and community resilience.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Gilead Foundation is the philanthropic arm of Gilead Sciences that invests in programs addressing social determinants of health, HIV prevention, community health workforce development, STEM education, and health equity. It channels grant funding to community-based organizations, NGOs, and emerging leaders through named programs such as the Community Health Worker Comprehensive HIV Prevention Initiative, Pedro Zamora Young Leaders Scholarship and Fellowship Program, STEM Careers Partnership, Creating Possible Fund, and Building Community Donations.

Product overview

Gilead Foundation is the philanthropic arm of Gilead Sciences focused on advancing health equity and addressing social determinants of health. The Foundation operates grant-making programs including the Pedro Zamora Young Leaders Scholarship (leadership development for HIV advocates), Community Health Worker Comprehensive HIV Prevention Initiative (CHW-led prevention in underserved communities), and STEM Careers Partnership (healthcare workforce pathways for youth). These programs are not traditional software products but rather public health and education grant initiatives.

Differentiator

Problem solved

Functional benefit

Brands

• Kite: CAR T-cell therapy subsidiary focused on cancer treatment
• Gilead Foundation
• Choose U
• Yeztugo
• AmBisome

Products and services

• Pedro Zamora Young Leaders Scholarship and Fellowship Program Leadership development scholarship and fellowship program for emerging HIV/AIDS advocates, delivered through the National AIDS Memorial partnership to develop the next generation of community leaders in the HIV response.
• Community Health Worker Comprehensive HIV Prevention Initiative Two-year initiative providing $12 million in funding to 33 community-based organizations to expand community health worker (CHW)-led HIV prevention models, training systems, and culturally tailored screening programs for HIV, STIs, mental health, and substance use in underserved communities.
• STEM Careers Partnership Two-year $1 million partnership with Boys & Girls Clubs of America supporting STEM education programs for youth interested in healthcare careers, preparing the next generation for medicine, science, and engineering.
• Creating Possible Fund Grant program under Gilead Foundation supporting innovative community-led health equity projects, part of the foundation's philanthropic giving portfolio alongside Building Community Donations.
• Building Community Donations Community donation program under Gilead Foundation that channels corporate giving to community-based health, education, and resilience initiatives.

Quantifiable outcome

• VL morbidity decreased by 82% in South East Asia
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

15 partnerships are on record, tiered core.

• National AIDS MemorialcoreStrategic or Co-development Partner · 11 June 2026Three-year approximately $3 million commitment to preserve HIV epidemic history, expand public education, and support leadership development through Pedro Zamora Young Leaders Scholarship and Fellowship Program. Initiative includes preservation of AIDS Memorial Quilt panels and support for National AIDS Memorial Grove in San Francisco.
• World Health Organization (WHO)coreStrategic or Co-development Partner · 21 May 2026Renewed five-year collaboration committing $9.2M and 400,000+ vials of AmBisome through 2030 to eliminate visceral leishmaniasis, focusing on high-burden countries in East Africa including Bangladesh, Ethiopia, Eritrea, India, Kenya, Nepal, Somalia, South Sudan, Sudan, Uganda, Yemen, Chad and Djibouti.
• 33 Community-Based Organizations (Bebashi, Allies in Hope, others)coreStrategic or Co-development Partner · 2 March 2026$12 million investment through two-year Community Health Worker Comprehensive HIV Prevention Initiative funding organizational infrastructure, CHW training systems, and culturally tailored programs including integrated screening for HIV, STIs, mental health, and substance use.
• BLK Room ProjectcoreGTM or Marketing Partner · 4 December 2025Partnership producing 'Risky Dinner Conversations' reaching 2.2M people through Black women influencers discussing sexual health and HIV awareness in Houston, Dallas, Chicago, Atlanta, Miami, and Oakland.
• Boys & Girls Clubs of AmericacoreStrategic or Co-development Partner · 16 October 2025Two-year $1 million partnership funding STEM programs aimed at youth interested in healthcare careers. Programs across several U.S. cities to prepare next generation for careers in medicine, science, and engineering.
• Global FundcoreStrategic or Co-development Partner · 1 September 2025Bridging strategy partner supplying lenacapavir at no profit for early access in LLMICs. First shipments delivered to Eswatini and Zambia in November 2025, marking first-time a new HIV medicine reached sub-Saharan Africa in same year as U.S./EU approvals.
• PEPFAR (U.S. President's Emergency Plan for AIDS Relief)coreStrategic or Co-development Partner · 1 September 2025Partnership to deliver twice-yearly lenacapavir for HIV prevention for up to two million people in primarily LLMICs, expanded to three million through 2028. PEPFAR leads country prioritization and implementation through existing systems.
• Dr. Reddy's LaboratoriescoreOEM/ Whitelabel/ Licensing Partner · 1 September 2025Voluntary licensee manufacturing and supplying generic lenacapavir for 120 primarily LLMICs. Partnership with Clinton Health Access Initiative enabling approximately $40 per person per year pricing.
• HeterocoreOEM/ Whitelabel/ Licensing Partner · 1 September 2025Voluntary licensee manufacturing and supplying generic lenacapavir for 120 primarily LLMICs. Partnership with Gates Foundation to enable supply at approximately $40 per person per year.
• Emcure PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 1 September 2025Voluntary licensee for generic lenacapavir manufacturing and supply across 120 primarily LLMICs.
• Eva PharmacoreOEM/ Whitelabel/ Licensing Partner · 1 September 2025Voluntary licensee for generic lenacapavir manufacturing and supply across 120 primarily LLMICs.
• Ferozsons LaboratoriescoreOEM/ Whitelabel/ Licensing Partner · 1 September 2025Voluntary licensee for generic lenacapavir manufacturing and supply across 120 primarily LLMICs.
• Mylan (Viatris)coreOEM/ Whitelabel/ Licensing Partner · 1 September 2025Voluntary licensee for generic lenacapavir manufacturing and supply across 120 primarily LLMICs.
• Medicines Patent Pool (MPP)coreStrategic or Co-development Partner · 1 September 2025Gilead was first pharmaceutical company to join MPP in 2011 to expand access to HIV and hepatitis B medicines through patent sharing in LLMICs.
• Clinton Health Access Initiative (CHAI)coreStrategic or Co-development Partner · 1 September 2025Partnership enabling supply of high-quality, low-cost generic lenacapavir for PrEP in LLMICs at approximately $40 per person per year, starting in 2027.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Johnson & Johnson Foundation: Corporate foundation of Johnson & Johnson supporting global health, health workforce, and frontline health worker initiatives. Comparable given its parallel emphasis on community health worker capacity building and disease-specific programs.
• Bill & Melinda Gates Foundation: Largest private philanthropic foundation globally with massive HIV, global health, and infectious disease programs. Comparable as a partner of Gilead on generic lenacapavir supply (Hetero partnership) and a major HIV funder shaping the global access landscape in which the foundation operates.
• Pfizer Foundation: Philanthropic arm of Pfizer supporting global health, STEM education, and health equity initiatives. Comparable as a large pharma corporate foundation with parallel health workforce and STEM grantmaking strategies.

Direct peers

• amfAR (Foundation for AIDS Research): Leading nonprofit dedicated to HIV/AIDS research, advocacy, and education. Comparable as a mission-aligned HIV foundation funding research grants and community programs for affected populations.
• ViiV Healthcare: HIV-focused pharmaceutical company majority-owned by GSK, with Pfizer and Shionogi as shareholders. Directly comparable as a dedicated HIV therapeutics company with global access programs including voluntary licensing and community-based prevention funding.
• Merck Foundation (MSD): Philanthropic foundation of Merck & Co. focused on global health, cancer, and health workforce capacity building. Operates a similar corporate foundation model with international disease-elimination grantmaking programs and STEM/health workforce initiatives.
• Elizabeth Glaser Pediatric AIDS Foundation: Pediatric HIV-focused foundation working on prevention, treatment, and advocacy globally. Comparable as a disease-specific HIV foundation operating funded programs in high-burden LLMICs with PEPFAR partnership.
• Elton John AIDS Foundation: HIV-focused philanthropic foundation funding community-based prevention, treatment, and stigma-reduction programs. Comparable as a dedicated HIV grantmaker with community-led funding models and emphasis on vulnerable populations.
• Bristol Myers Squibb Foundation: Philanthropic arm of Bristol Myers Squibb focused on health equity and disease-specific grantmaking. Comparable as a major pharma corporate foundation executing disease-focused grant portfolios with global health equity programs.

Others

• Clinton Health Access Initiative (CHAI): Global health organization partnering with governments and pharmaceutical companies to enable low-cost medicine access in LLMICs. Comparable as a direct partner of Gilead Foundation on the ~$40/person/year generic lenacapavir pricing arrangement for 120 LLMICs.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/GileadSciences
• LinkedInlinkedin.com/company/gilead-sciences
• Instagraminstagram.com/gileadsciences
• Facebookfacebook.com/GileadSciences

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments32 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gilead Foundation